Armata Total Liab from 2010 to 2025

ARMP Stock  USD 1.79  0.22  10.95%   
Armata Pharmaceuticals Total Liabilities yearly trend continues to be relatively stable with very little volatility. Total Liabilities is likely to grow to about 141.2 M this year. Total Liabilities is the total amount of all liabilities that Armata Pharmaceuticals has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
1993-12-31
Previous Quarter
149.2 M
Current Value
134.5 M
Quarterly Volatility
33.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Selling General Administrative of 12.5 M or Total Revenue of 4 M, as well as many indicators such as Price To Sales Ratio of 28.2, Days Sales Outstanding of 256 or Invested Capital of 0.0. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Total Liab Growth Pattern

Below is the plot of the Total Liab of Armata Pharmaceuticals over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Armata Pharmaceuticals' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Armata Total Liab Regression Statistics

Arithmetic Mean41,780,112
Geometric Mean18,916,057
Coefficient Of Variation119.01
Mean Deviation38,959,391
Median20,659,000
Standard Deviation49,722,562
Sample Variance2472.3T
Range139.3M
R-Value0.75
Mean Square Error1154.5T
R-Squared0.56
Significance0.0008
Slope7,844,551
Total Sum of Squares37085T

Armata Total Liab History

2025141.2 M
2024134.5 M
2023130.4 M
202259.8 M
202144.4 M
202020.7 M
201910.9 M

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Total Liab, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Liabilities134.5 M141.2 M

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.